argenx and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: argenx and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions
Released on: January 22, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Debbie Allen, Vice President, Business Development at argenx & Tero Wennberg, Business Development Manager at Leo Pharma explain the rationale behind their new collaboration to PharmaVentures' Fintan Walton during BIO in Philadelphia.
  • Summary
  • Transcript
  • Participants
  • Company
Debbie Allen, Vice President, Business Development at argenx & Tero Wennberg, Business Development Manager at Leo Pharma explain the rationale behind their new collaboration to PharmaVentures' Fintan Walton during BIO in Philadelphia.
Debbie Allen, Vice President, Business Development at argenx & Tero Wennberg, Business Development Manager at Leo Pharma explain the rationale behind their new collaboration to PharmaVentures' Fintan Walton during BIO in Philadelphia.
arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions
arGEN-X
We apply our unique suite of human antibody technologies to disease targets that are underserved in the biotherapeutics space. Combining our technology strengths with our antibody development capabilities and the complementary skills of our scientists enables us to create highly differentiated antibody programs - for our own pipeline and in collaboration with our partners. How we win Our antibody discovery platform, SIMPLE Antibody™, delivers human antibodies with distinctive therapeutic qualities against even the most challenging disease targets. Having the power to break into unchartered target territory is taking us beyond the boundaries of traditional antibody technologies. Complementing the strengths of SIMPLE Antibody™, our state-of-the-art capabilities in Fc engineering (NHance™, ABDEG™ and POTELLIGENT®) are creating antibody programs with first- and/or best-in-class therapeutic product potential.